A new closed tube, scalable, 96-well based solution to meet
clinical demand for respiratory testing
AUSTIN, Texas, Oct. 19, 2015 /PRNewswire/ -- Luminex Corporation
(NASDAQ: LMNX) today announced that it has received CE-IVD marking
for its NxTAG® Respiratory Pathogen Panel. The Panel detects
21 clinically-relevant viral and bacterial respiratory pathogens,
including the atypical bacteria Chlamydophila pneumoniae,
Mycoplasma pneumoniae, and Legionella pneumophila.
The NxTAG Respiratory Pathogen Panel is the only respiratory assay
that easily enables laboratories to simultaneously detect 21
respiratory pathogens in a single closed tube system that scales to
accommodate changes in throughput needed to respond to seasonal
changes in demand, such as during flu season.
Photo -
http://photos.prnewswire.com/prnh/20151016/277903
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
The NxTAG Respiratory Pathogen Panel requires only minutes of
hands-on time with no upstream reagent preparation. The simplified
workflow allows extracted samples to be added directly to
pre-plated, lyophilized reagents. The tubes are then sealed and
ready for closed tube amplification and subsequent detection using
the Luminex MAGPIX® instrument. The innovative tube strip design
offers laboratories the flexibility to manage variable sample
demand by processing a single sample or up to as many as 96 samples
per run, without wasting consumables or reagents, or the need to
have full batches. Total turnaround time is just over three hours
for 96 samples (excluding extraction).
In addition, the accompanying SYNCT™ Software provides a
comprehensive approach to data analysis and reporting, and enables
the NxTAG Respiratory Pathogen Panel to integrate easily into any
laboratory. Any of a number of targets can be selected by
laboratories to customize their testing panel.
"With the NxTAG Respiratory Pathogen Panel, we found that
shorter hands-on and turnaround times, together with a simpler
closed tube process, made for an impressively streamlined
workflow. The workflow, combined with a small instrument
footprint, really answered our lab's need for fast, reliable,
comprehensive respiratory testing," said Professor Hans H. Hirsch, M.D., Head of the Division
Infection Diagnostics and Transplantation & Clinical Virology
at the University of Basel,
Switzerland.
"As a leader in multiplexed solutions, we are excited to launch
the next generation NxTAG Respiratory Pathogen Panel which
delivers expanded coverage and a simple closed tube workflow,
combined with the throughput and quality of results established by
the xTAG Respiratory Viral Panel," said Thomas Pracht,
Managing Director, EMEIA, Luminex Corporation. "With the
CE-IVD marking of the NxTAG Respiratory Pathogen Panel, we
continue to focus on delivering solutions that address our
customers' productivity needs."
To learn more, please visit Luminex at:
http://www.luminexcorp.com/NxTAG-RPP
Why Test for Respiratory Pathogens?
Many commonly
encountered respiratory pathogens (viral and bacterial) have
similar clinical presentation, making diagnosis based on symptoms
alone very difficult. Influenza viruses commonly cause respiratory
illness, but many other pathogens may cause significant impact on
patient health as well. Respiratory syncytial virus (RSV), as one
example, is the most common cause of severe respiratory illness in
young children, as well as a leading cause of death from
respiratory illness in those aged 65 years and
older.1
Clinicians need to accurately detect the respiratory pathogen
causing illness in their patients in order to effectively prescribe
treatment and control the spread of infection. Laboratories need
respiratory assays that can rapidly and efficiently detect these
relevant pathogens with minimal hands-on time and no post-PCR
handling to meet laboratory, physician, and patient needs.
About Luminex Corporation
Luminex is
committed to applying its passion for innovation toward creating
breakthrough solutions to improve health and advance science. The
company is transforming global healthcare and life-science research
through the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP® open-architecture
multi-analyte platform, MultiCode® real-time polymerase chain
reaction (PCR), and multiplex PCR-based technologies, that deliver
cost-effective rapid results to clinicians and
researchers. Luminex's technologies are commercially
available worldwide and in use in leading clinical laboratories, as
well as major pharmaceutical, diagnostic, biotechnology and
life-science companies. Luminex is meeting the needs of
customers in markets as diverse as clinical diagnostics,
pharmaceutical drug discovery, biomedical research including
genomic and proteomic research, personalized medicine, biodefense
research and food safety. For further information on Luminex
Corporation and the latest advances in multiplexing using
award winning technology, please visit
http://www.luminexcorp.com/.
Media Contact
Christine
Valle, 512.219.8020
Sr. Manager, Global Marketing
cvalle@luminexcorp.com
Investor Contact
Harriss
Currie, 512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com
1. Seasonal Influenza & Other Respiratory Viruses. Centers
for Disease Control (Internet). Cited 2015 March. Available from:
http://www.cdc.gov/flu/about/qa/other.htm.